| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Finance > Some Factors Bank Managers Consider Before Granting Loans |
|
Digg It - Some Factors Bank Managers Consider Before Granting Loans
There are many factors which may influence the granting of loans by most Bank Managers and a number o According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product f them are outlined below; 1. The type of Account The Customer operates: Although non-account owners ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in get loans, loans are normally given to current account owners more than those who operate savings acc lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ounts. 2. The Amount Involved: If it is a large sum of loan, the Bank Manager will consider whether here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe f such an amount is removed, it will not affect the financial standing of the bank. 3.The Past Finan d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ial Dealings of the Customer with the Bank: one with sound past financial dealings with a bank has a ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc higher chance of getting a loan and vice versa. 4. The Purpose for which the loan will be used: fina easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi cially yielding projects are considered more buy bank managers in order to make sure that the loan wi nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ll be used for projects that will yield profit so that it will enable the borrower to repay the loan and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ 5.The Collateral Security Offered:These collateral securities which are fixed assets must be the th ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ngs the bank can sell easily and more than the value of the loan given. 6. The Period of Repayment: ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a The period of re-payment of such loan is very important because, the Bank would not want its loan to dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod e tied down for a very long time in spite of the fact that it changes interest on the loan. 7. The C cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ustomers Referee: The referee must be one who is well known to the bank and who will guarantee that i tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen case the borrower defaults or becomes insolvent, that he will repay the loan. 8. The Earning Power t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel f The Customer: The person's earnings vis-a-vis the amount to be given out as loan are some of the de ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust termining factors in granting and issuing loans. 9. The Sources of Re-payment: The Bank Managers wil y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products also like to know the possible sources the customer intending to borrow loans has for repaying the l . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de oan. 10. The Present Government Policy on Bank Lending: A Customer may fulfill all the "Conditions" elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ut if government policy on lending is credit squeeze, the Bank will not grant the Loan and vice versa tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Business Financing - Short - Term Working Capital Management What Constitutes a Complete and Effective SEO Campaign?
|